Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1769)	12/31/2001 3:41:38 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 2515

Frankly, I think the market is being way too kind to the stock given what a total f.u. the application was. No getting around the fact that, for the immediate challenges facing the company (fda approval), this group does not know what it's doing. I've sold some today as it could be a year before we see sales. I just can't hang on hoping this BLA can be fixed in 8-10 weeks. It was always my hope that there be revenues in the door to support valuation assumptions before the patent challenge arose. Without that long lead, which is definitely shorter now and may be a lot shorter, the patent challenge when it comes will appear even more threatening. This could be the beginning of a whipsaw, but really....how can you not include every piece of raw data from the single pivotal trial, especially considering it was only a P2 on refractory patients? What, was it INCONVENIENT? Glad I own some abgx. Wilder, revising Favorites.